Low Dose Cyclophosphamide in Combination with Elotuzumab - a Novel Immunotherapeutic Strategy for Multiple Myeloma

被引：0
|
作者：
Feerick, Claire L. [1 ,2 ,3 ]
Lynch, Kevin [2 ,3 ,4 ]
Krawczyk, Janusz [2 ,5 ,6 ]
O'Dwyer, Michael [2 ,5 ,6 ]
Ryan, Aideen [1 ,2 ,3 ,4 ,6 ]
机构：
[1] NUI Galway, Sch Med, Coll Med,Nursing & Hlth Sci, Discipline Pharmacol & Therapeut, Galway, Ireland
[2] NUI Galway, Sch Med, Coll Med, Nursing & Hlth Sci, Galway, Ireland
[3] NUI Galway, Regenerat Med Inst REMEDI, Sch Med,Nursing & Hlth Sci, Coll Med, Galway, Ireland
[4] Galway Univ Hosp, Dept Hematol, Galway, Ireland
[5] Blood Canc Network Ireland, Galway, Ireland
[6] NUI Galway, SFI Res Ctr Med Devices, CURAM, Galway, Ireland
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152432
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
    Gormley, Nicole J.
    Ko, Chia-Wen
    Deisseroth, Albert
    Nie, Lei
    Kaminskas, Edvardas
    Kormanik, Natasha
    Goldberg, Kirsten B.
    Farrell, Ann T.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6759 - 6763
  • [32] Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients
    Waal, Esther G. M. de
    de Munck, Linda
    Hoogendoorn, Mels
    Woolthuis, Gerhard
    van der Velden, Annette
    Tromp, Yvonne
    Vellenga, Edo
    Hovenga, Sjoerd
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (05) : 720 - 725
  • [33] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra A.
    Mann, Mason L.
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD, 2019, 134
  • [34] Phase I Study of Elotuzumab (HuLuc63) in Combination with Bortezomib in Relapsed Multiple Myeloma
    Jakubowiak, A. J.
    Bensinger, W.
    Zimmerman, T.
    Chanan-Khan, A.
    Singhal, A.
    Siegel, D.
    Anderson, K. C.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S45 - S45
  • [35] Elotuzumab, a new promising therapeutic class, in combination with lenalidomide and dexamethasone in the treatment of relapsed multiple myeloma
    Richez, Valentine
    Legros, Laurence
    Leleu, Xavier
    HEMATOLOGIE, 2016, 22 (01): : 16 - 17
  • [36] A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Richardson, Paul Gerard Guy
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc
    Facon, Thierry
    Vij, Ravi
    Reece, Donna Ellen
    White, Darrell
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn Scott
    Singhal, Anil
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
    Jakubowiak, A. J.
    Benson, D. M., Jr.
    Bensinger, W.
    Siegel, D. S.
    Zimmerman, T. M.
    Mohrbacher, A.
    Richardson, P. G.
    Afar, D.
    Singhal, A. K.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed multiple myeloma
    Kropff, Martin
    Liebisch, Peter
    Wand, Hannes
    Weisel, Katja
    Gann, Claudia-Nanette
    Knop, Stefan
    Einsele, Hermann
    BLOOD, 2007, 110 (11) : 1053A - 1053A
  • [39] Peripheral blood stem cell (PBSC) mobilization in patients with multiple myeloma: Low dose versus intermediate dose cyclophosphamide
    Hiwase, DK
    Schwarer, AP
    McKendrick, JJ
    Bollard, GM
    Hiwase, SD
    Michael, BM
    BLOOD, 2005, 106 (11) : 822A - 823A
  • [40] GPRC5D as a novel immunotherapeutic target in multiple myeloma
    Karthik Nath
    Bruno A. Costa
    Sham Mailankody
    Nature Reviews Clinical Oncology, 2023, 20 : 281 - 282
12345